Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Exercise of Warrants and Issue of Equity Total Voting Rights ABINGDON, OXFORDSHIRE, UK / ACCESSWIRE / March 30, 2023 / Biodexa Pharmaceuticals PLC (AIM:BDRX)(NASDAQ:BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has today issued to various investors 6,218,265 new ordinary shares of £0.02 each in the Company ("New Ordinary Shares"), pursuant to exercise notices in respect of 1,243,653 B Warrants received yesterday. All A Warrants and B Warrants have now been exercised and all such warrants were exercised on a cashless basis.

News for Biodexa Pharmaceuticals Plc Stock (BDRX)